In 1-2 punch, Mol­e­c­u­lar Tem­plates cuts first-gen can­di­date and los­es a Big Phar­ma part­ner; Charles Riv­er teams up with Va­lence to pro­vide AI dis­cov­ery plat­form

It’s been sev­er­al months since a treat­ment-re­lat­ed death led the FDA to put a par­tial hold on Mol­e­c­u­lar Tem­plates’ on­ly first-gen­er­a­tion en­gi­neered tox­in body (ETB) can­di­date. Now the com­pa­ny is nix­ing the pro­gram, and Take­da is re­turn­ing the rights to one of its next-gen can­di­dates.

MT-3724, Mol­e­c­u­lar’s EBT in de­vel­op­ment for non-Hodgkin lym­phoma, will be no more, the com­pa­ny said on Mon­day morn­ing. The FDA first placed a par­tial hold on the can­di­date in No­vem­ber, fol­low­ing the death of a Phase II pa­tient who ex­pe­ri­enced Grade 5 cap­il­lary leak syn­drome.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER